~~<i id='D86F9E7544'><strike id='D86F9E7544'><tt id='D86F9E7544'><pre id='D86F9E7544'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：Wikipedia 2025-09-05 09:11:38 - browse：9957

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： The system is set up to fail children with medical complexity

Wikipedia

leisure time

knowledge

leisure time

Wikipedia

AdobeTheFoodandDrugAdministrationispoisedtotelldrugandmedicaldevicemakershowtobetterincludepeopleofc

WSS

Questions and answers about ramping up H5N1 bird flu vaccine

Liver decline slowed by off

NIH tests clinical research in primary care with $30 million program

Study: Why relieving medical debt did not improve financial outcomes

Cigna wins case to block Amy Bricker's move to CVS

Listen: More tumult at BIO & coercive care for sickle cell patients

leisure time

Wikipedia

Wikipedia

At least 13 dead in Texas as scorching temps continue

The system is set up to fail children with medical complexity

Peter Hotez and the public health issue of online harassment

Liver decline slowed by off

What does generative AI mean for health care? We asked experts

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Medicare proposal to cover medical devices draws a mixed reaction

Stephen Quake on the Chan Zuckerberg quest to conquer disease

leisure time

Eyeing GLP

UnitedHealth argues against case alleging wrongful AI care denials

The system is set up to fail children with medical complexity

Pharma companies must ensure equitable access to obesity drugs

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Digital health: a case of mistaken identity

knowledge

leisure time

Wikipedia

Wikipedia